KROMATID Showcases Genomic Instability Benchmarking Work at ASGCT

A LinkedIn post from KROMATID highlights an upcoming scientific presentation at the American Society of Gene & Cell Therapy (ASGCT) meeting. The post notes that VP of Platform Erin Cross will present work on establishing chromosome-scale benchmarks for detecting genomic instability in gene-edited cell therapies.

According to the post, the research focuses on using high-depth cytogenetic analysis within an “Analytics and Assay Development – Biosafety” session. The work is described as aiming to help development teams move from descriptive genomic data toward more predictive, decision-oriented frameworks.

For investors, the presentation suggests that KROMATID is positioning its platform around safety analytics in gene-edited cell therapies, an area of growing regulatory and commercial importance. If the benchmark methodology gains traction with drug developers or regulators, it could enhance KROMATID’s role in assay development workflows and strengthen its competitive standing in genomic integrity and cell therapy analytics.